These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29959213)

  • 1. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
    Beaino W; Nedrow JR; Anderson CJ
    Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
    Beaino W; Anderson CJ
    J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma.
    Pun MD; Gallazzi F; Ho KV; Watkinson L; Carmack TL; Iweha E; Li L; Anderson CJ
    Mol Pharm; 2024 Jun; 21(6):2960-2969. PubMed ID: 38680059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Al
    Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
    J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
    Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
    J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
    Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
    J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Imaging of VLA-4 in a New BRAF
    Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
    Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Metal-Free DOTA-Conjugated
    Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
    Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary evaluation of
    Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
    Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of [
    Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
    Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
    Jiang M; Ferdani R; Shokeen M; Anderson CJ
    Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
    Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
    J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma.
    Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X
    Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of
    Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
    Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
    Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 20. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
    Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
    Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.